Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers like Insys Therapeutics and Cara Therapeutics that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Arena Pharmaceuticals’ pipeline currently consists of three clinical-stage therapies and a small handful of partnered programs.